This activity will address the increasing use of biomarker testing in the management of patients with non-small cell lung cancer, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.
The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.

The goal of this initiative is to increase clinicians’ knowledge and improve their competence in understanding the latest advances in targeting genomic pathways for the treatment of non-small cell lung cancer (NSCLC) through a review of the current and ongoing research/clinical trials focused on

The rapid pace of updates to the NCCN Guidelines for Non-small Cell Lung Cancer makes it challenging for health care providers to stay informed about the newest recommendations, including side effects with these agents. Health care providers need to be aware of the latest NCCN recommendations to improve care for their patients with metastatic NSCLC.
The rapid pace of updates to the NCCN Guidelines for Non-Small Cell Lung Cancer makes it challenging for health care providers to stay informed about the newest recommendations. Health care providers need to be aware of the latest NCCN recommendations to improve care for their patients with metastatic NSCLC.
As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers.
Before a specific multidisciplinary treatment plan is recommended for an individual patient, multidisciplinary evaluation in tumor boards is often advised to ensure the patient receives the most appropriate treatment. The multidisciplinary team approach has been shown to improve outcomes in patients with lung cancer.
Nurses and other health care providers need to be familiar with the new approved agents (and their corresponding molecular biomarkers) and side effects associated with the newer agents, so they can improve care for their patients.

This module will feature members of the NSCLC care team presenting best practice protocols for integrating biomarker testing and discussing practical challenges such as timing, sequencing versus broad panel testing, and the roles of the interdisciplinary team.

This module will feature members of the NSCLC care team presenting best practice protocols for integrating biomarker testing and discussing practical challenges such as timing, sequencing versus broad panel testing, and the roles of the interdisciplinary team.

Pages

Subscribe to RSS - Lung Cancers